Ying Cheng

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R. Spigel, Byoung Chul Cho et al. · New England Journal of Medicine · 2024 · 275 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant

Wen‐Feng Fang, Yuanyuan Zhao, Yongzhong Luo et al. · JAMA · 2024 · 168 citations · Full text

Medicine, Oncology, Pharmacology +16

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

Ying Cheng, Yun Fan, Yanqiu Zhao et al. · Journal of Thoracic Oncology · 2024 · 132 citations · Full text

Medicine, Oncology, Pharmacology +4

Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.

Ying Cheng, Liang Han, Lin Wu et al. · Journal of Clinical Oncology · 2022 · 35 citations

Medicine, Oncology, Pharmacology +17

A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.

Jian Li, Jun Zhao, Baoshan Cao et al. · Journal of Clinical Oncology · 2022 · 33 citations

Medicine, Oncology, Pharmacology +13